Studies clash on Russian vaccine’s efficacy against Omicron variant

Moscow, December 17

The developer of Russia’s Sputnik V said Friday that its vaccine provides the best protection against the Omicron variant of the coronavirus, disputing a Western study which found Sputnik produced no antibodies against the new variant.

The Gamaleya Institute and the Russian Direct Investment Fund, which bankrolled Sputnik V and its one-shot version called Sputnik Light, said in a statement that a preliminary laboratory study showed Sputnik V had “the best virus neutralisation results against Omicron in comparison with other vaccines”.

Russian President Vladimir Putin praised Sputnik V efficiency against Omicron earlier on Friday.

“Our Sputnik V is working well, and, perhaps, even more effective against the Omicron than other vaccines used,” the President said during a congress of the Russian Union of Industrialists and Entrepreneurs.

Meanwhile, international researchers from the University of Washington and the Swiss drugmaker Humabs Biomed SA said in a study published on Tuesday in pre-print and yet to be peer-reviewed that data they analysed showed conflicting results.

The study, which used samples from health care workers in Buenos Aires, Argentina, who received Sputnik V, showed “no neutralising activity against Omicron”.

Russia has so far reported 25 cases of the Omicron variant in the country, according to Deputy Prime Minister Tatiana Golikova. — AP